Advertisement

Topics

Neurotech’s macular telangiectasia treatment sees positive phase 2 results

17:30 EDT 20 Jun 2017 | Healio

A phase 2 trial of NT-501 found the therapy had a beneficial effect in patients with macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.Patients in the multicenter, randomized clinical trial had a statistically significant reduction in the progressive loss of photoreceptors in treated vs. untreated eyes at 24 months, the release said.

Original Article: Neurotech’s macular telangiectasia treatment sees positive phase 2 results

NEXT ARTICLE

More From BioPortfolio on "Neurotech’s macular telangiectasia treatment sees positive phase 2 results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...